このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

脆弱X症候群(FXS)の成人男性を対象としたガボクサドールのプラセボ対照単回投与負荷試験

2026年9月8日 更新者:Craig Erickson

This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded fashion.

調査の概要

状態

完了

条件

介入・治療

研究の種類

介入

入学 (実際)

10

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Ohio
      • Cincinnati、Ohio、アメリカ、45229
        • Cincinnati Children's Hospital Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~40年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

説明

Inclusion Criteria:

  1. Subject consents to participate, or if they are not their own legal guardian, offers assent supported by legally authorized representative consent
  2. Subject is willing and able to comply with the study procedures as specified in the protocol and to comply with the study drug administration. Caregiver also commits to the study requirements prior to any study-related procedures
  3. Subject and caregiver are both able to understand the spoken national language clearly and caregiver can read and write to complete study assessments
  4. Males age 18 to 40 years (inclusive)
  5. Has FXS with molecular genetic confirmation of the full FMR1 mutation (>200 cysteine-guanine-guanine [CGG] repeats). May have been confirmed historically or at Screening
  6. Is in general good health as deemed by the Investigator, determined by physical examination, medical history, and laboratory tests
  7. If receiving serotonin-selective reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or serotonin antagonist and reuptake inhibitor (SARI), is on a stable, well-tolerated dose for the previous 3 months with no further changes anticipated
  8. Is not sexually active or can confirm at least one form of contraceptive

Exclusion Criteria:

  1. Any chronic major medical comorbid condition deemed by the Investigator as presenting added risk to the subject, including but not limited to, refractory hypertension, kidney disease, or liver disease
  2. Diagnosed with diabetes (Type 1 or II) or receiving any anti-diabetic medication
  3. Unstable seizure disorder, defined by any seizure within 6 months prior to baseline visit and/or a change in any anti-convulsant drug dosing in the 60 days prior to study consent
  4. Changes in psychotropic or anti-convulsant (where taken for reasons other than seizure control) drug treatment within 30 days prior to Screening
  5. Significant changes in any educational, behavioral, and/or dietary interventions the month prior to Screening
  6. Planned initiation of new, or modification of ongoing, interventions during the study
  7. Unable or unwilling to take oral medication (whole capsule, despite assistance with a spoonful of applesauce, yoghurt, or equivalent liquid food)
  8. Consumption of liver enzyme inducers or inhibitors including and not limited to foods, medicines, herbal remedies and supplements three days prior to any Visit. Foods or beverages containing CYP3A4/5 inhibitors (e.g., grapefruit, pomegranate, pomelo, and star fruit) should be avoided before taking study medication and for up to 1 hour post dose throughout the study
  9. Has abnormal baseline laboratory assessments including, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin >1.5 × the upper limit of normal (ULN), serum creatinine >1.5 x ULN or other clinically relevant laboratory abnormality
  10. Has a clinically significant heart rate or blood pressure (BP) at Screening as judged by the Investigator
  11. Has received an investigational drug in any prior clinical study within 30 days or 5 half-lives (whichever is longer) prior to Screening

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Placebo in lab, Gaboxadol in home, Gaboxadol in lab, Placebo in home

Individuals in this condition received Placebo in lab, Gaboxadol in home, Gaboxadol in lab, then Placebo in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

実験的:Gaboxadol in lab, Gaboxadol in home, Placebo in lab, Placebo in home

Individuals in this condition received Gaboxadol in lab, Gaboxadol in home, Placebo in lab, then Placebo in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

実験的:Placebo in lab, Placebo in home, Gaboxadol in lab, Gaboxadol in home

Individuals in this condition received Placebo in lab, Placebo in home, Gaboxadol in lab, then Gaboxadol in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

実験的:Gaboxadol in lab, Placebo in home, Placebo in lab, Gaboxadol in home

Individuals in this condition received Gaboxadol in lab, Placebo in home, Placebo in lab, then Gaboxadol in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Target Engagement of Gaboxadol Treatment on EEG Power
時間枠:Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in EEG recordings with gaboxadol treatment (assessed at pre-dose, 60 minutes post-dose, average response across home and lab reported). compared with pre-dose on resting theta, alpha and gamma band absolute power. Absolute power measures reflect the median power averaged across 129 electrodes in μV²/Hz. Means are presented using the average of home and lab values.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Target Engagement of Gaboxadol Treatment on Auditory Chirp
時間枠:Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on brain response to auditory chirp stimuli), as measured by intertrial phase coherence (ITC). Means are presented using the average of home and lab values.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

二次結果の測定

結果測定
メジャーの説明
時間枠
To Investigate the Feasibility of Home Research Visits and Procedures in Adult Males With FXS
時間枠:Pre-dose, 60 minutes post-dose

Quality and test-retest reliability of assessments performed at home compared with the hospital setting. This includes blood testing for Fragile X messenger ribonucleoprotein (FMRP: range of 0-40 picomolar) and eye-tracking of eye gaze to eye regions when viewing faces (range of value from 0 percent to 100 percent; higher values are associated with a neurotypical phenotype).

Pre-dose, 60 minutes post-dose
To Investigate the Feasibility of High Density EEG Recording at Home in Adult Males With FXS
時間枠:Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42

This endpoint examined the reliability of pre-dose resting-state EEG absolute power estimates between in-lab and in-home assessments using intraclass correlation (ICC). ICCs were calculated separately for 129 electrodes using absolute power estimates (μV²/Hz). The reported ICC represents the mean ICC across electrodes, with the standard deviation reflecting variability in ICC values across electrodes. whole-head, pre-dose resting state EEG power estimates from data collected in-lab vs in-home using intraclass correlation (ICC).

Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42
To Potentially Explore the Pharmacokinetics of Gaboxadol Treatment in Single-dose Trial Design
時間枠:Sixty minutes post-dose on 4 study visits, up to day 42

PK profile (the level of gaboxadol in human plasma) will be obtained at 60 +/- 10 minutes post-dose only).

Sixty minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments
時間枠:Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in cognitive and neuropsychological assessment measures with gaboxadol treatment (RBANS List Learning). During the RBANS List Learning subtests, participants listen to a list of 10 words and repeat back as many as they can remember four times, for a maximum score of 40. Change scores were calculated by subtracting pre-dose words remembered from post-dose words remembered, with positive scores meaning an improvement in memory.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Eye Tracking Assessments
時間枠:Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Change in eye tracking outcomes (60-90 minutes post-dose compared to pre-dose on percent viewing of social versus geometric scene

Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Clinician-rated Measures
時間枠:Post-dose on 4 study visits, up to day 42

Score on the Clinical Global Impressions - Improvement (CGI-I) scale, a clinician rating scale with "1" anchored to "very much improved" and "7" anchored to "very much worse."

Post-dose on 4 study visits, up to day 42
To Determine Whether FMRP Levels Predict Treatment Response
時間枠:Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Relationship between FMRP (Fragile X messenger ribonucleoprotein) level and degree of change (baseline/screen to post-dose) across measures

Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Cragi A Erickson, MD、Children's Hospital Medical Center, Cincinnati

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年1月29日

一次修了 (実際)

2025年5月13日

研究の完了 (実際)

2025年6月24日

試験登録日

最初に提出

2024年3月8日

QC基準を満たした最初の提出物

2024年3月19日

最初の投稿 (実際)

2024年3月28日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月8日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2023-0795

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。